摘要
目的:研究并分析左西孟旦联用托伐普坦在重症瓣膜性心脏病外科围手术期的临床应用效果。方法:选取我院心脏外科在2015年10月-2018年6月心脏外科行手术治疗的重症心脏瓣膜病患者60例,将患者分为研究组和对照组,每组均为30例患者。在常规治疗基础上,研究组于术前给予1次左西孟旦治疗,术后对照组给于托伐普坦片口服,研究组在给予托伐普坦片口服的基础上加用左西孟旦注射液。结果:研究组病例在术后12h、术后24h、术后36h、术后48h之心肌肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB)、B型尿钠肽(BNP)水平低于对照组;在两组病例术后并发症发生率的对比中,对照组患者1例死亡,研究组并发症发生率明显低于对照组。结论:在重症瓣膜性心脏病外科围手术期使用左西孟旦联和托伐普坦可以增强对心脏的保护,减少并发症的产生,值得临床推广与应用。
Objective:To analyze the clinical effect of leosimendan in the perioperative period of severe valvular heart disease.Methods:60 cases with severe valvular heart disease in our cardiac surgery department in October 2015-Jun 2018 were equally divided into research group and control group.On the basis of conventional treatment,the study group was given one treatment of leosimendan before operation.The control group was giventolvaptan tablets after operation,while the study group was given leosimendan injection with olvaptan tablets.Result:The levels of cardiac troponin I(cTnI),creatine kinase isoenzyme(CK-MB)and brain natriuretic polypeptide(BNP)of the study group were all lower than those of the control group at 12 h,24 h,36 hand 48 hafter the operation.In the comparison of postoperative complications between the two groups,one patient died in the control group,and the incidence of complications in the study group was significantly lower than that in the control group.Conclusion:The use of leosimendan combine the tolvaptan in the perioperative period of severe valvular heart surgery can enhance the protection of the heart,reduce the occurrence of complications,and improve the success rate of surgery.
出处
《健康之路》
2018年第12期1-2,共2页
Health Way
关键词
左西孟旦
重症瓣膜性心脏病
围手术期治疗
Leosimendan
Severe valvular heart disease
Perioperative treatment
